Islatravir

Gilead and Merck announce Phase 2 study results showing islatravir and lenacapavir combination maintained 94.2% viral suppression at 48 weeks, advancing to Phase 3 for potential weekly oral HIV treatment.

Gilead and Merck report Phase 2 data showing a treatment switch to an investigational oral once-weekly combination of islatravir and lenacapavir maintained viral suppression in adults at Week 48, with 94.2% of participants achieving HIV-1 RNA <50 copies/mL.

HIVR4P 2024 conference highlights safety of dapivirine vaginal ring during early pregnancy, no interactions between long-acting injectable cabotegravir (CAB-LA) PrEP and long-acting reversible contraceptives (LARCs), early-stage HIV vaccine findings showing potential to generate broadly neutralizing antibodies, discovery of monocytes expressing IL1B associated with smaller HIV reservoirs, and a novel refillable controlled-release antiretroviral drug implant for PrEP and ART.

Gilead Sciences to present new findings from antiviral research at IDWeek 2024, including data from HIV, COVID-19, and viral hepatitis studies, highlighting commitment to treating and preventing viral diseases.

Merck to present over 40 data on vaccines, antibacterials, and antivirals at IDWeek 2024, including full Phase 2b/3 trial results of clesrovimab for RSV prevention in infants.

Gilead Sciences discusses its focus areas in virology, oncology, and inflammation/immunology, highlighting successful data in HIV prevention with lenacapavir. The company also mentions progress in its liver franchise and oncology portfolio, including the potential launch of a BCMA cell therapy. Gilead expects growth driven by new product launches and anticipates sharing more data later this year.

Lenacapavir (Sunlenca®), developed by Gilead Sciences Inc., is a long-acting HIV capsid inhibitor available as an oral tablet and injectable solution, allowing bi-annual administration. Approved in the EU in August 2022 for multi-drug resistant HIV-1 infection, it inhibits viral replication at multiple stages. It's part of a collaboration with Merck Sharp & Dohme for HIV treatment development.